In September 2020, the U.S. Food and Drug Administration (FDA) required the boxed warning be updated for all benzodiazepine medicines to describe the risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions consistently across all the medicines in the class. Common Common side effects include fever, drooling, and constipation. Post-marketing experience * Hives. * Rashes. Warnings and precautions In December 2013, the FDA added warnings to the label for<unk> , that it can cause serious skin reactions, Stevens–Johnson syndrome, and toxic epidermal necrolysis, especially in the first eight weeks of treatment. Drug interactions * Alcohol increases bioavailability by 50%; compounded depressant effect may precipitate life-threatening toxicity. * Cimetidine increases the effects of<unk> . * Valproate. Overdose Overdose and intoxication with benzodiazepines, including<unk> , may lead to CNS depression, associated with drowsiness, confusion, and lethargy, possibly progressing to ataxia, respiratory depression, hypotension, and coma or death. The risk of a fatal outcome is increased in cases of combined poisoning with other CNS depressants, including alcohol. Abuse potential and addiction Classic (non-anxioselective) benzodiazepines in animal studies have been shown to increase reward-seeking behaviours which may suggest an increased risk of addictive behavioural patterns.<unk>  abuse has been reported in some countries, according to a 1983 World Health Organisation report. Dependence and withdrawal In humans, tolerance to the anticonvulsant effects of<unk>  may occur and withdrawal seizures may occur during abrupt or overrapid withdrawal.<unk>  as with other benzodiazepine drugs can lead to physical dependence, addiction, and what is known as the benzodiazepine withdrawal syndrome. Withdrawal from<unk>  or other benzodiazepines after regular use often leads to withdrawal symptoms which are similar to those seen during alcohol and barbiturate withdrawal. The higher the dosage and the longer the drug is taken, the greater the risk of experiencing unpleasant withdrawal symptoms. Benzodiazepine treatment should only be discontinued via a slow and gradual dose reduction regimen.
Clobazam
Ketazolam
Midazolam
Mexazolam
Remimazolam
Adinazolam
Triazolam
Flutazolam